Last reviewed · How we verify

NCT03121105: IIDD

Pathologic-MRI Findings in Atypical IIDD

Completed Last updated 7 May 2018
What this trial tests

trial in Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System in 25 participants. Completed in 31 December 2017.

Timeline
1 January 2017
Primary endpoint
1 December 2017
31 December 2017

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusCompleted
Study typeOBSERVATIONAL
Enrollment25
Start date1 January 2017
Primary completion1 December 2017
Estimated completion31 December 2017

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our objective is to describe the pathologic and MRI findings in a series of patients with presumed demyelinating lesion of the central nervous system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03121105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing